comparison with the corresponding period last year ending 30 June 2016 We have committed ourselves to strategies that emphasized on building up strong fundamentals in order to drive our businesses towards a

, up from 0.38 times as of 31 December 2016. Yours sincerely, Pongsarn Klongwathanakith (Pongsarn Klongwathanakith) Chief Financial Officer

equity was 0.80 times, up from 0.38 times as of 31 December 2016. Yours sincerely, Pongsarn Klongwathanakith (Pongsarn Klongwathanakith) Chief Financial Officer

through the purchase of equity in the Target Company to the Executive Committee; and/or Chief Executive Officer; and/or any persons delegated by the Executive Committee and/or the Chief Executive Officer to

ratio to 44.5% from 39.6%. Overall Gross profit was up 13.5% YoY from THB 591mn to THB 670mn, while Gross profit margin decreased to 55.5% (prior year: 60.4%). In light of the ongoing expansion, selling

% of paid up capital, Total investment 50 Millions baht. The acquisition of BS Myco Biotech shares will result in the BS Myco Biotech being a subsidiary of the Company. The Company signed the share

Manufactory (Malaya) Sdn Bhd (“FKRMM”) from Consistent Record Sdn Bhd MYR which accounted for 100% of total paid-up capital of FKRMM. Payment in acquiring transaction equal to 53,000,000 MYR or equivalent to

construction and not listed in the Stock Exchange of Thailand, amount of 4,000,000 (“Four Million shares”) shares or 17.39% of paid up capital which is 23,000,000 shares (“Twenty-Three Million shares”) at par

“Company”) would like to provide the clarification on the business operation for the 3rd Quarter of the year 2017 ended 30 September 2017. The Company set up a subsidiary company, which registered as a

. The Company is committed to the long ter m success of JASIF. Its commitment to lock- up 19 per cent of the total number of units of JASIF as provided at the IPO of JASIF remains unchanged. In